95 related articles for article (PubMed ID: 17607915)
1. Resistance-associated signatures in breast cancer.
Györffy B
Recent Results Cancer Res; 2007; 176():37-50. PubMed ID: 17607915
[TBL] [Abstract][Full Text] [Related]
2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
3. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced tumor gene expression changes in human breast cancers.
Lee SC; Xu X; Lim YW; Iau P; Sukri N; Lim SE; Yap HL; Yeo WL; Tan P; Tan SH; McLeod H; Goh BC
Pharmacogenet Genomics; 2009 Mar; 19(3):181-92. PubMed ID: 19352302
[TBL] [Abstract][Full Text] [Related]
5. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line.
Kubiliūtė R; Šulskytė I; Daniūnaitė K; Daugelavičius R; Jarmalaitė S
Medicina (Kaunas); 2016; 52(5):298-306. PubMed ID: 27746118
[TBL] [Abstract][Full Text] [Related]
6. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
7. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Smith L; Watson MB; O'Kane SL; Drew PJ; Lind MJ; Cawkwell L
Mol Cancer Ther; 2006 Aug; 5(8):2115-20. PubMed ID: 16928833
[TBL] [Abstract][Full Text] [Related]
8. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
10. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
12. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes.
Hu Y; Pang E; Lai PB; Squire JA; MacGregor PF; Beheshti B; Albert M; Leung TW; Wong N
Int J Oncol; 2004 Nov; 25(5):1357-64. PubMed ID: 15492826
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay.
Kurbacher CM; Cree IA; Brenne U; Bruckner HW; Kurbacher JA; Mallmann P; Andreotti PE; Krebs D
Breast Cancer Res Treat; 1996; 41(2):161-70. PubMed ID: 8944334
[TBL] [Abstract][Full Text] [Related]
20. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Satherley K; de Souza L; Neale MH; Alexander RA; Myatt N; Foss AJ; Hungerford JL; Hickson ID; Cree IA
J Pathol; 2000 Oct; 192(2):174-81. PubMed ID: 11004693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
